Future brightening for depression treatments.
Holden
Constance
C
D000328:Adult; D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001921:Brain / Q000503:physiopathology; D002648:Child; D002986:Clinical Trials as Topic; D003346:Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D003863:Depression / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D003866:Depressive Disorder / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D015259:Dopamine Agents / Q000627:therapeutic use; D004599:Electric Stimulation Therapy; D004565:Electroconvulsive Therapy; D006801:Humans; D008280:Magnetics; D009474:Neurons / Q000502:physiology; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011613:Psychotherapy; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D013315:Stress, Psychological / Q000188:drug therapy / Q000503:physiopathology; D013373:Substance P / Q000037:antagonists & inhibitors
D000928:Antidepressive Agents; D015259:Dopamine Agents; D010726:Phosphodiesterase Inhibitors; D016194:Receptors, N-Methyl-D-Aspartate; D013373:Substance P; D003346:Corticotropin-Releasing Hormone